Howard Rutman, MD, Vice President of Medical Affairs at Daiichi Sankyo, discusses the typical diagnostic journey for patients with tenosynovial giant cell tumors (TGCT).
TGCT are a group of rare, benign tumors that involve the synovium, bursae and tendon sheath. While these tumors are benign, they can grow and cause extreme damage to the surrounding tissues. The typical treatment for TGCT is surgical removal of the tumor but other options, such as the FDA-approved CSF1R inhibitor, pexidartinib, can be effective.
Symptoms of TGCT can include pain, swelling, and limitation of movement of the joint. According to Dr. Rutman, this can make diagnosing patients with TGCT difficult as the presentation often resembles arthritis or other common health problems. This often forces patients to see multiple physicians before being correctly diagnosed.
For more information about TGCT, visit https://checkrare.com/tenosynovial-giant-cell-tumor-tgct/